Dan Shan,Xiaoyan Tang,Renqiang Liu,Dan Pan,Xijun Wang,Jinying Ge,Zhiyuan Wen,Zhigao Bu

Virol Sin.2022 Jan 12;S1995-820X(22)00002-5.doi: 10.1016/j.virs.2022.01.002. Online ahead of print.

Abstract

Severe acute respiratory syndrome (SARS) is a highly contagious zoonotic disease caused by SARS coronavirus (SARS-CoV). Since its outbreak in Guangdong Province of China in 2002, SARS has caused 8096 infections and 774 deaths by December 31st, 2003. Although there have been no more SARS cases reported in human populations since 2004, the recent emergence of a novel coronavirus disease (COVID-19) indicates the potential of the recurrence of SARS and other coronavirus disease among humans. Thus, developing a rapid response SARS vaccine to provide protection for human populations is still needed. Spike (S) protein of SARS-CoV can induce neutralizing antibodies, which is a pivotal immunogenic antigen for vaccine development. Here we constructed a recombinant chimeric vesicular stomatitis virus (VSV) VSVΔG-SARS, in which the glycoprotein (G) gene is replaced with the SARS-CoV S gene. VSVΔG-SARS maintains the bullet-like shape of the native VSV, with the heterogeneous S protein incorporated into its surface instead of G protein. The results of safety trials revealed that VSVΔG-SARS is safe and effective in mice at a dose of 1 × 106 TCID50. More importantly, only a single-dose immunization of 2 × 107 TCID50 can provide high-level neutralizing antibodies and robust T cell responses to non-human primate animal models. Thus, our data indicate that VSVΔG-SARS can be used as a rapid response vaccine candidate. Our study on the recombinant VSV-vectored SARS-CoV vaccines can accumulate experience and provide a foundation for the new coronavirus disease in the future.

Keywords: Immunization; Severe acute respiratory syndrome coronavirus (SARS-CoV); Vaccine; Vesicular stomatitis virus (VSV).

Copyright © 2022 The Authors. Publishing services by Elsevier B.V. All rights reserved.